Tezepelumab for Severe Asthma

(PASSAGE Trial)

Recruiting in Palo Alto (17 mi)

+38 other locations

Overseen by Njira Lugogo., MD.

Age: Any Age

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 4

Waitlist Available

Sponsor: AstraZeneca

No Placebo Group

Prior Safety Data

Approved in 2 Jurisdictions

Trial Summary

What is the purpose of this trial?

This trial tests an injectable medication called tezepelumab for people with severe asthma who need high doses of inhaled steroids and have frequent asthma attacks. The medication works by reducing inflammation in the airways to help improve breathing and decrease asthma attacks.

Eligibility Criteria

This trial is for adults and adolescents (12 years or older) with severe asthma who've had at least 2 exacerbations in the past year, are on medium to high dose inhaler steroids plus another controller medication, and are under a specialist's care. They must be eligible for tezepelumab per US guidelines but not have used other biologics recently or be part of another asthma study.

Inclusion Criteria

I have been on a medium to high dose asthma treatment for at least a year.

Currently receiving care from specialist physicians (eg, pulmonologists and/or allergists).

My doctor has approved me for tezepelumab treatment as per US guidelines.

Exclusion Criteria

Participation in an interventional clinical trial for asthma within 12 months prior to enrollment.

Judgment by the Investigator that the participant is unlikely to comply with study procedures, restrictions, and requirements.

I haven't used asthma biologics for 4 months or 5 half-lives before joining.

Participant Groups

The trial is testing the effectiveness and safety of tezepelumab in treating severe asthma. It focuses on diverse populations within the United States that haven't been studied much before.

Group I: Tezepelumab Experimental Treatment 1 Intervention

Participants will be receiving 210 mg of tezepelumab every 4 weeks (Q4W) from Week 0 until Week 48.

Tezepelumab is already approved in United States, European Union for the following indications:

🇺🇸 Approved in United States as Tezspire for:

• Severe asthma

🇪🇺 Approved in European Union as Tezspire for:

• Severe asthma

Find a Clinic Near You

Research Locations Nearby Select from list below to view details:

Research Site Vancouver, WA

Research Site Boston, MA

Research Site Los Angeles, CA

Research Site New Orleans, LA

More Trial Locations

Who Is Running the Clinical Trial?

AstraZeneca Lead Sponsor

Parexel Industry Sponsor

References